Tradename:

Kapron

Composition:

Each tablet contains:

Tranexamic acid 500 mg

Auxiliary components:

microcrystalline cellulose, hyprolose, sodium carboxymethyl starch, talc, colloidal silicon dioxide, calcium stearate.

Shell composition: hypromellose, titanium dioxide, talc, macrogol.

Properties:

Tranexamic acid is an antifibrinolytic agent that specifically inhibits the activation of profibrinolysin (plasminogen) and its conversion to fibrinolysin (plasmin). It has a local and systemic hemostatic effect in

bleeding associated with increased fibrinolysis, as well as anti-inflammatory, anti-allergic, antiinfectious and antitumor effects by suppressing the formation of kinins and other active peptides involved in allergic and inflammatory reactions. The experiment confirmed the own analgesic activity of tranexamic acid, as well as the supercumulative potentiating effect on the analgesic activity of opiates.

Indications:

– bleeding or the risk of bleeding against the background of increased fibrinolysis, as generalized (bleeding during operations and in the postoperative period, postpartum bleeding, manual separation of the placenta, chorionic detachment, bleeding during pregnancy, malignant neoplasms of the pancreas and prostate glands, hemophilia, hemorrhagic complications of fibrinolytic therapy, thrombocytopenic purpura, leukemia, liver disease, previous streptokinase therapy), and local (uterine, cervical conization for carcinoma, nasal, pulmonary, gastrointestinal bleeding, hematuria, bleeding after prostatectomy, to extraction in patients with hemorrhagic diathesis);

-operative interventions on the bladder;

-surgical manipulations for systemic inflammatory reactions (sepsis, peritonitis, pancreatic necrosis, severe and moderate preeclampsia, shock of various etiologies and other critical conditions).

Method of administration and dosage:

Inside, regardless of the meal.

Short-term treatment of bleeding caused by increased fibrinolysis: the recommended standard dose of tranexamic acid is 15-25 mg / kg of body weight, on average 1000-1500 mg 2-3 times / day.

For prostatectomy and surgical interventions on the bladder: 1000 mg 6 hours before surgery, then 1000 mg 3-4 times / day until gross hematuria disappears. It is not recommended to use the drug for more than 2 weeks after surgery.

The average duration of treatment is 7 days.

The dose for children is 25 mg / kg.

Contraindications:

-increased sensitivity to the drug;

– subarachnoid hemorrhage.

With caution: thrombohemorrhagic complications (in combination with heparin and indirect anticoagulants), thrombosis (deep vein thrombophlebitis, thromboembolic syndrome, myocardial infarction), color vision disturbances, hematuria from the upper urinary tract (possible obstruction by a blood clot), renal ).

Precautions:

When combined with hemostatic drugs and hemocoagulase, activation of thrombus formation is possible. Before starting and during treatment, it is necessary to conduct an examination by an ophthalmologist (visual acuity, color vision, fundus).

Side effects:

Allergic reactions (rash, pruritus, urticaria), dyspeptic symptoms (anorexia, nausea, vomiting, heartburn, diarrhea), dizziness, weakness, drowsiness, tachycardia, pain in a tight cage, hypotension (with rapid intravenous administration), color vision disturbance, blurred visual perception; thrombosis or thromboembolism (the risk of developing is minimal).

Storage method:

At a temperature not higher than 30 degrees.

Packaging:

The cardboard box holds 2 blisters of 10 tablets.